ArticleNeuro-oncology advances
The invasive proteome of glioblastoma revealed by laser-capture microdissection.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses.EMBO reports · 2026Article
- Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis.Clinical proteomics · 2026Article
- Identifying Key Pathogenic Mechanisms in Recurrent Glioblastoma Through Bioinformatics Analysis.Current medicinal chemistry · 2026Article
- Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes.Cancer gene therapy · 2024Article
- EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes.Oncogene · 2023Article
- Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis.EMBO molecular medicine · 2022Article
- Article
- Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells.Frontiers in cell and developmental biology · 2022Article
- Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes.International journal of molecular sciences · 2021Article
- EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration.Journal of cell science · 2020Article
- Membrane proteomic profiling to identify candidate therapy targets for glioblastoma infiltration.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastomas are heterogeneous tumors composed of a necrotic and tumor core and an invasive periphery.
methodsHere, we performed a proteomics analysis of laser-capture micro-dissected glioblastoma core and invasive areas of patient-derived xenografts.
resultsBioinformatics analysis identified enriched proteins in central and invasive tumor areas. Novel markers of invasion were identified, the genes proteolipid protein 1 (PLP1) and Dynamin-1 (DNM1), which were subsequently validated in tumors and by functional assays.
conclusionsIn summary, our results identify new networks and molecules that may play an important role in glioblastoma development and may constitute potential novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.